Clostridium Difficile Diagnostics and Treatment Market: Global Size, Trends, Competitive, and Historical & Forecast Analysis, 2019-2025 – Increased prevalence of clostridium difficile infection and increase in research and development are the key drivers for Global Clostridium Difficile Diagnostics and Treatment Market.
Clostridium difficile diagnostics and treatment Market is valued around USD 1362.99 Million in 2018 and expected to reach USD 2320.83 Million by 2025 with the CAGR of 7.9% over the forecast period.
Clostridium difficile colitis results from disruption of normal, healthy bacteria in the colon, often as a result of antibiotics. Clostridium difficile is caused by clostridium difficile bacteria which is common infection among older adults. Prevalence of healthcare-associated infections has been one of the major drivers of the global clostridium difficile diagnostics and treatment market. In 2011 C. difficile was estimated to cause about half a million infections among adults in United States due to which ~29,000 people died within 30 days of the initial diagnosis. During the study of global clostridium difficile diagnostics and treatment market, we have considered clostridium difficile diagnostics and treatment product type and test type to analyze the market.
Global Clostridium difficile diagnostics and treatment market report is segmented on the basis of product type, test type, and distribution channel and by regional & country level. Based upon product type, global clostridium difficile diagnostics and treatment market is classified as metronidazole, vancomycin, fidaxomicin, and bezlotoxumab and others. Based upon test type, global Clostridium difficile diagnostics and treatment Market is classified as enzyme immunoassays, real-time polymerase chain reaction (RT-PCR), nucleic amplification tests (NAAT), and Others. Based upon distribution channel, global clostridium difficile diagnostics and treatment market is classified as hospitals & clinics, diagnostic laboratories, and pharmacies.
The regions covered in this Clostridium difficile diagnostics and treatment Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Clostridium Difficile Diagnostics and Treatment is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Browse The Full Report@ https://www.brandessenceresearch.com/healthcare/clostridium-difficile-diagnostics-and-treatment-market/
Key Players for Global Clostridium Difficile Diagnostics and Treatment Market Reports–
Global clostridium difficile diagnostics and treatment market report covers prominent players like Thermo Fisher Scientific Inc., Actelion Pharmaceuticals, Baxter International Inc., Alere, Inc., Pfizer, Inc., Novartis AG, Trinity Biotech, Summit Therapeutics, Sanofi S.A., AstraZeneca Plc., Merck & Co., and others.
Increase in the Prevalence of Clostridium Difficile and Vast Product Pipeline of Therapies
The commercialization and growth of global clostridium difficile diagnostics and treatment market over the past 25 years has been highly impactful. One of the major factors driving the growth of clostridium difficile diagnostics and treatment market over the forecast period is increased prevalence of clostridium difficile infection. As per Centers for Disease Control and Prevention, clostridium difficile infection is the most common healthcare-associated infection among adults. In 2011 C. difficile was estimated to cause about half a million infections among adults in United States due to which ~29,000 people died within 30 days of the initial diagnosis.
Moreover, increase in research and development activities coupled with technological advancement led to the development of novel therapies and diagnostics are expected to support the growth of clostridium difficile diagnostics and treatment market in coming years.
North America is Expected to Dominate the Clostridium Difficile Diagnostics and Treatment Market
North America dominates the market with highest market share over the forecast period due to the increased prevalence of clostridium difficile infection coupled with advanced healthcare facilities and high per capita income. Europe is expected to the second largest growing region over the forecast period due to the technological advancements and research and development activities. Asia Pacific is expected to be the third largest and fastest growing region over the forecast period. Due to the lack of awareness among people, increase in per capita income and presence of various generic players in the region are expected to promote the growth of clostridium difficile diagnostics and treatment market over the forecast period. Latin America, Middle East and Africa are expected to develop considerably over the forecast period.
Key Benefits for Global Clostridium Difficile Diagnostics and Treatment Market Reports –
• Global market report covers in depth historical and forecast analysis.
• Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.
• Global market report helps to identify opportunities in market place.
• Global market report covers extensive analysis of emerging trends and competitive landscape.
Clostridium Difficile Diagnostics and Treatment Market Segmentation –
By Product Type
• Metronidazole
• Vancomycin
• Fidaxomicin
• Bezlotoxumab
• Others
By Test Type
• Enzyme Immunoassays
• Real-Time Polymerase Chain Reaction (RT-PCR)
• Nucleic Amplification Tests (NAAT)
• Others
By Distribution Channel
• Hospitals & Clinics
• Diagnostic Laboratories
• Pharmacies
By Region
• North America
• S.
• Canada
• Europe
• UK
• France
• Germany
• Italy
• Asia Pacific
• China
• Japan
• India
• Southeast Asia
• Latin America
• Brazil
• Mexico
• Middle East and Africa
• GCC
• Africa
• Rest of Middle East and Africa
Clostridium Difficile Diagnostics and Treatment Market key Players
Merck & Co.
Thermo Fisher Scientific Inc.
Actelion Pharmaceuticals
Baxter International Inc.
Alere, Inc.
Pfizer, Inc.
Novartis AG
Trinity Biotech
Summit Therapeutics
Sanofi S.A.
AstraZeneca Plc.